Kolon TissueGene plunged again, failing to sustain the previous trading day's rebound as supply and demand instability persisted due to uncertainty surrounding its U.S. clinical trials. After recording a new 52-week low during the session, the stock partially recovered its losses, but there were limits to restoring investor sentiment.

On the 28th, Kolon TissueGene on the KOSDAQ market closed at 14,560 won, down 1,350 won (8.49%) from the previous trading day.

The stock opened at 15,910 won, the same as the previous day's closing price. It attempted a rebound early in the session, rising to 16,310 won, but sell orders flooded in rapidly, turning it downward. The intraday low was 13,880 won, matching the 52-week low on the market quotation screen.

After hitting the bottom, bargain-hunting buying flows helped the stock recover to the 14,500-won range, but the decline still exceeded 8%. The difference between the day's high and low was 2,430 won. Trading volume reached 5,064,508 shares with a transaction value of 74.75 billion won, reflecting fierce trading battles in an expanded volatility range.

Kolon TissueGene had previously recorded lower limits for three consecutive trading days from the 21st to the 23rd, resulting in a sharp decline. While a rebound was attempted afterward on perceptions of excessive losses and bargain hunting, selling pressure regained dominance on this day, confirming that short-term supply and demand instability has not been resolved.

The core variable shaking the stock price is uncertainty related to U.S. clinical trials. With the need for confirmation on clinical development schedules, responses from regulatory authorities, and future procedures, investors are exhibiting a risk-averse attitude.

However, as the stock price has plunged in a short period, bargain-hunting buying has been repeatedly flowing in during the session. The fact that the stock pared its losses after falling to 13,880 won on this day suggests a clash between buying and selling forces across various price levels.

Based on the market quotation screen, Kolon TissueGene's market capitalization stands at 1.2372 trillion won, ranking 60th on the KOSDAQ. Foreign investors hold 4,494,500 shares, with a foreign ownership rate of 5.29%.

Going forward, the key factor will be whether buying support can be sustained near the 52-week low of 13,880 won. Whether increased trading volume leads to additional selling or connects to a recovery in supply and demand will be the variable that determines the short-term stock price. Over the medium to long term, the core checkpoints for a revaluation of the company's value include procedures related to U.S. clinical trials, the company's official explanations, the concrete progression of clinical schedules, and the resolution of regulatory uncertainty.

[This article was written for investment reference purposes, and we are not responsible for investment decisions made on this basis or their results. This article was partially assisted by AI.]